Atmofizer Technologies Inc. announced the latest testing performed by a third-party laboratory on Atmofizer ONE technology demonstrated a greater than 4-log reduction (> 99.99%) in specifically targeted microorganisms, including gram-positive bacteria, gram-negative bacteria, and enveloped virus. The Atmofizer ONE is now marketed subject to the U.S. Food and Drug Administration's "Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency" (March 2020). Atmofizer's patented agglomeration technology is designed to: Aggregate airborne nanoparticles into more-addressable particulates; Use acoustic pressure to cluster the smallest airborne particulates and microorganisms, before exposure to ultraviolet light, Increase the size of airborne ultra-fine particles, Not emit ozone, or use ionization, Reduce household odors.

Atmofizer ONE Performance Update: Atmofizer Efficacy Claims: 99.99% reduction of Klebsiella Aerogenes [gram-negative bacteria], 99.99% reduction of Staphylococcus Epidermis [gram-positive bacteria], 99.99% reduction of Phi-6 Bacteriophage [enveloped virus, Surrogate for SARS-CoV-2]. Atmofizer SARS-CoV-2 Specific Efficacy Claims: Atmofizer reduces airborne SARS-CoV-2, Atmofizer destroys over 99.99% SARS-CoV-2 without a filter, Atmofizer destroys SARS-CoV-2 by over 99.99% in 45 minutes. These results are based on third-party laboratory tests at 180 minutes of continuous device operation.

The Food and Drug Administration (FDA) has not evaluated Atmofizer technology. Atmofizer ONE has not been reviewed or approved by the FDA. SARS-CoV-2 data is based on Third-Party Testing of Phi-6 Bacteriophage, a surrogate microorganism for SARS-CoV-2.